Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
866 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07335003 | Study of the Photoprotection and Prevention of Actinic Damage With Anthelios Fluide 100 KA+ UVMune 400 in Patients With Multiple Actinic Keratoses | recruiting | N/A | 80 | Cosmetique Active InternationalINDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06366789 | Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 150 | Lomond Therapeutics Holdings, Inc.INDUSTRY |
| 4 |
| Dec 31, 2025 |
| clinicaltrials |
| NCT05957081 | Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309(MarkV-01) | recruiting | Phase 1 | 67 | PharmAbcineINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07165067 | A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 36 | AP Biosciences Inc.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT07197827 | A Study of YL242 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 424 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 3 | Dec 24, 2025 | clinicaltrials |
| NCT06392477 | A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 96 | SanofiINDUSTRY | 5 | Dec 23, 2025 | clinicaltrials |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 230 | TORL Biotherapeutics, LLCINDUSTRY | 12 | Dec 23, 2025 | clinicaltrials |
| NCT06478693 | A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC | recruiting | Phase 1 | 70 | Myeloid TherapeuticsINDUSTRY | 3 | Dec 18, 2025 | clinicaltrials |
| NCT07051525 | Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and Fever(ELSA-Adult) | recruiting | N/A | 214 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06782971 | Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX(COSMOS-Avatar) | recruiting | — | 25 | Clinical Hub for Interventional Research (CHOIR)OTHER_GOV | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05366153 | Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer(REDEEM-CAD) | recruiting | — | 748 | Baker Heart and Diabetes InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06961565 | PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas | recruiting | Phase 1 | 56 | Pasithea Therapeutics Corp.INDUSTRY | 3 | Dec 4, 2025 | clinicaltrials |
| NCT06237803 | European Myeloma Network (EMN) Sample Project(EMN36) | recruiting | — | 6,000 | European Myeloma Network B.V.NETWORK | 10 | Dec 3, 2025 | clinicaltrials |
| NCT07244705 | A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC | recruiting | Phase 1 / Phase 2 | 66 | Anbogen Therapeutics, Inc.INDUSTRY | 2 | Nov 24, 2025 | clinicaltrials |
| NCT05914116 | A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 862 | DualityBio Inc.INDUSTRY | 4 | Nov 21, 2025 | clinicaltrials |
| NCT06184035 | A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer(Tumorad) | recruiting | Phase 1 / Phase 2 | 90 | Spago Nanomedical ABINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07030998 | Wearable Technology and Machine Learning for Early Detection and Risk Assessment of Unacceptable Toxicities in a Paediatric Oncology Cohort(WEARABLES) | recruiting | — | 150 | Murdoch Childrens Research InstituteOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05024929 | Targeted Therapy to Increase RAI Uptake in Metastatic DTC | recruiting | — | 32 | Children's Hospital of PhiladelphiaOTHER | 2 | Nov 14, 2025 | clinicaltrials |
| NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 120 | CRISPR Therapeutics AGINDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT06249048 | Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | recruiting | Phase 1 / Phase 2 | 108 | Strand Therapeutics Inc.INDUSTRY | 2 | Oct 29, 2025 | clinicaltrials |
| NCT02848274 | ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome | recruiting | — | 2,000 | Stanford UniversityOTHER | 7 | Oct 22, 2025 | clinicaltrials |
| NCT06174987 | A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) | recruiting | Phase 3 | 50 | Daiichi SankyoINDUSTRY | 12 | Oct 15, 2025 | clinicaltrials |
| NCT06784193 | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 180 | Olema Pharmaceuticals, Inc.INDUSTRY | 2 | Oct 10, 2025 | clinicaltrials |
| NCT04370587 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | ImmVira Pharma Co. LtdINDUSTRY | 2 | Oct 8, 2025 | clinicaltrials |
| NCT07202052 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202065 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202078 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202091 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05184582 | Physical Exercise During Preoperative Chemotherapy for Breast Cancer(Neo-ACT) | recruiting | N/A | 712 | Karolinska InstitutetOTHER | 4 | Sep 22, 2025 | clinicaltrials |
| NCT06536257 | Personalised Immunotherapy Platform(PIP-PREDICT) | recruiting | — | 1,000 | Melanoma Institute AustraliaOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05807035 | Autologous Tumour Vaccine Trial | recruiting | Phase 1 | 30 | Vaxine Pty LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06868199 | A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 87 | LaNova Medicines LimitedINDUSTRY | 2 | Sep 12, 2025 | clinicaltrials |
| NCT06351904 | A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy | recruiting | Phase 1 | 72 | Ractigen Therapeutics.OTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT07158918 | ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 65 | ABL Bio, Inc.INDUSTRY | 3 | Sep 8, 2025 | clinicaltrials |
| NCT06092580 | Phase 1 Study of AWT020 in Advanced Cancer | recruiting | Phase 1 | 60 | Anwita BiosciencesINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06806982 | A Study of VRN101099 in Patients With HER2-Positive Solid Tumors | recruiting | Phase 1 | 72 | Voronoi, IncINDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05180942 | Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS(SOCRATES) | recruiting | — | 130 | Monash UniversityOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT03850574 | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia(TUSCANY) | recruiting | Phase 1 / Phase 2 | 240 | Aptose Biosciences Inc.INDUSTRY | 6 | Aug 26, 2025 | clinicaltrials |
| NCT06907043 | A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.(EIK1004-001) | recruiting | Phase 1 / Phase 2 | 130 | Eikon TherapeuticsINDUSTRY | 3 | Aug 19, 2025 | clinicaltrials |
| NCT05725291 | AMT-116 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Multitude Therapeutics Inc.INDUSTRY | 3 | Aug 17, 2025 | clinicaltrials |
| NCT04429542 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | recruiting | Phase 1 | 292 | Bicara TherapeuticsINDUSTRY | 3 | Aug 15, 2025 | clinicaltrials |
| NCT05906862 | AMT-253 in Patients With Selected Advanced Solid Tumours | recruiting | Phase 1 | 54 | Multitude Therapeutics (Australia) Pty LtdINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05659732 | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer | recruiting | Phase 1 | 32 | PharmaEngineINDUSTRY | 2 | Jul 31, 2025 | clinicaltrials |
| NCT06307015 | De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE)(DE-RADIATE) | recruiting | N/A | 25 | Royal North Shore HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06929663 | A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 48 | AkesoINDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07063875 | Adding IL-2 to Tebentafusp to Eradicate Cancer Progression(SILVER) | recruiting | Phase 1 / Phase 2 | 8 | St Vincent's Hospital, SydneyOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05560659 | Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy(POPSTAR II) | recruiting | Phase 2 | 92 | Peter MacCallum Cancer Centre, AustraliaOTHER | 2 | Jul 11, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials